Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 82.68
(-0.39%)
INR 82.68
(-0.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.28 Billion INR | -79.95% |
| 2022 | 11.42 Billion INR | -4.82% |
| 2021 | 11.99 Billion INR | -1.24% |
| 2020 | 12.15 Billion INR | -1.17% |
| 2019 | 12.29 Billion INR | -7.99% |
| 2018 | 13.36 Billion INR | -11.91% |
| 2017 | 15.16 Billion INR | -5.57% |
| 2016 | 16.06 Billion INR | -5.62% |
| 2015 | 17.01 Billion INR | 3.18% |
| 2014 | 16.49 Billion INR | 3.44% |
| 2013 | 15.94 Billion INR | 4.85% |
| 2012 | 15.2 Billion INR | 10.07% |
| 2011 | 13.81 Billion INR | 19.6% |
| 2010 | 11.55 Billion INR | 39.84% |
| 2009 | 8.26 Billion INR | 38.36% |
| 2008 | 5.97 Billion INR | 26.4% |
| 2007 | 4.72 Billion INR | 22.27% |
| 2006 | 3.86 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -9.31 Billion INR | -506.84% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 2.28 Billion INR | 0.0% |
| 2023 Q2 | 10.68 Billion INR | 0.0% |
| 2023 FY | 2.28 Billion INR | -79.95% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 11.42 Billion INR | -4.82% |
| 2022 Q4 | 11.42 Billion INR | 0.0% |
| 2022 Q2 | 11.71 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 11.99 Billion INR | -1.24% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 11.76 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 11.99 Billion INR | 0.0% |
| 2020 Q4 | 12.15 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 12.15 Billion INR | -1.17% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 12.22 Billion INR | 0.0% |
| 2019 Q4 | 12.29 Billion INR | 0.0% |
| 2019 Q2 | 13.02 Billion INR | 0.0% |
| 2019 FY | 12.29 Billion INR | -7.99% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 13.36 Billion INR | -11.91% |
| 2018 Q4 | 13.36 Billion INR | 0.0% |
| 2017 FY | 15.16 Billion INR | -5.57% |
| 2016 FY | 16.06 Billion INR | -5.62% |
| 2015 FY | 17.01 Billion INR | 3.18% |
| 2014 FY | 16.49 Billion INR | 3.44% |
| 2013 FY | 15.94 Billion INR | 4.85% |
| 2012 Q4 | 15.2 Billion INR | 0.0% |
| 2012 FY | 15.2 Billion INR | 10.07% |
| 2012 Q2 | 30.23 Billion INR | 0.0% |
| 2011 FY | 13.81 Billion INR | 19.6% |
| 2010 FY | 11.55 Billion INR | 39.84% |
| 2009 FY | 8.26 Billion INR | 38.36% |
| 2008 FY | 5.97 Billion INR | 26.4% |
| 2007 FY | 4.72 Billion INR | 22.27% |
| 2006 FY | 3.86 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 85.932% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.496% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 55.81% |
| Granules India Limited | 22.95 Billion INR | 90.026% |
| Indoco Remedies Limited | 10.34 Billion INR | 77.863% |
| Achyut Healthcare Limited | 2.01 Million INR | -113633.78% |
| Ajanta Pharma Limited | 10.71 Billion INR | 78.624% |
| Alkem Laboratories Limited | 48.6 Billion INR | 95.29% |
| Alpa Laboratories Limited | 307.12 Million INR | -645.457% |
| Brooks Laboratories Limited | 248.6 Million INR | -820.938% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 37.465% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 52.966% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -8.564% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.86% |
| Eris Lifesciences Limited | 38.26 Billion INR | 94.017% |
| FDC Limited | 3.7 Billion INR | 38.276% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.484% |
| Gufic Biosciences Limited | 5.59 Billion INR | 59.115% |
| Ipca Laboratories Limited | 33.74 Billion INR | 93.215% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -671.486% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 23.015% |
| Lasa Supergenerics Limited | 541.92 Million INR | -322.468% |
| Laurus Labs Limited | 42.71 Billion INR | 94.64% |
| Lupin Limited | 96.23 Billion INR | 97.621% |
| Mankind Pharma Limited | 23.87 Billion INR | 90.411% |
| Medicamen Biotech Limited | 940.36 Million INR | -143.465% |
| Medico Remedies Limited | 438.24 Million INR | -422.417% |
| Megasoft Limited | 1.85 Billion INR | -23.545% |
| NATCO Pharma Limited | 10.53 Billion INR | 78.262% |
| Piramal Pharma Limited | 74 Billion INR | 96.906% |
| RPG Life Sciences Limited | 1.38 Billion INR | -65.879% |
| Sigachi Industries Limited | 2.53 Billion INR | 9.553% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.753% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -12.547% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -96.485% |
| Unichem Laboratories Limited | 8.06 Billion INR | 71.627% |
| Wanbury Limited | 3.15 Billion INR | 27.446% |
| Windlas Biotech Limited | 1.76 Billion INR | -29.884% |
| ZIM Laboratories Limited | 2.08 Billion INR | -10.03% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 96.811% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 41.189% |
| Divi's Laboratories Limited | 18.99 Billion INR | 87.944% |
| Hester Biosciences Limited | 3.59 Billion INR | 36.31% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 10.61% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -192.089% |
| Bal Pharma Limited | 2.51 Billion INR | 8.833% |
| Strides Pharma Science Limited | 37.68 Billion INR | 93.924% |
| Venus Remedies Limited | 1.39 Billion INR | -64.378% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 72.251% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 79.591% |
| Shilpa Medicare Limited | 12.93 Billion INR | 82.297% |
| Aarti Drugs Limited | 11.5 Billion INR | 80.099% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 63.825% |
| Suven Life Sciences Limited | 148.62 Million INR | -1440.469% |
| Ind-Swift Limited | 13.45 Billion INR | 82.982% |
| Valiant Laboratories Limited | 1.05 Billion INR | -116.342% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 78.619% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 83.813% |
| Themis Medicare Limited | 1.88 Billion INR | -21.295% |
| Hikal Limited | 12.99 Billion INR | 82.382% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.21% |
| Sequent Scientific Limited | 8.27 Billion INR | 72.33% |
| Novartis India Limited | 1.8 Billion INR | -27.115% |
| Wockhardt Limited | 39.87 Billion INR | 94.258% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 96.264% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -692.752% |
| Neuland Laboratories Limited | 5.49 Billion INR | 58.363% |
| Morepen Laboratories Limited | 4.45 Billion INR | 48.664% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -255.571% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -15.845% |